



PATENT  
Docket No. 249.0002 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dominic E. COSGROVE ) Group Art Unit: 1641  
Serial No.: 09/970,318 )  
Confirmation No.: 1885 )  
Filed: 03 October 2001 )  
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER  
SYNDROME TYPE IIA

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, Applicant further requests that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Information Disclosure Statement is submitted with a Request for Continued Examination (RCE), it is believed that no fee is due. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

**INFORMATION DISCLOSURE STATEMENT**

Applicant(s): Dominic E. COSGROVE  
Serial No.: 09/970,318  
Filed: 03 October 2001  
For: IMMUNODIAGNOSTIC DETERMINATION OF USHER  
SYNDROME TYPE IIA

---

The Examiner is invited to contact Applicant's Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

Respectfully submitted for

Dominic E. COSGROVE

By  
Mueiting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Phone: (612)305-1220  
Facsimile: (612)305-1228  
**Customer Number 26813**

April 25, 2005  
Date

NAJ/kjm

By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

---

**CERTIFICATE UNDER 37 CFR §1.10:**

"Express Mail" mailing label number: EV 201 891 848 US Date of Deposit: 25 APRIL 2005

I hereby certify that the Transmittal Letter and the paper(s) and/or fee(s), as described hereinabove, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to: **Mail Stop RCE**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Sara E. Olson  
Name: SARA E. OLSON

---



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 249.0002 0101	<b>Serial No.:</b> 09/970,318
	<b>Applicant(s):</b> Dominic COSGROVE	<b>Confirmation No.:</b> 1885
	<b>Application Filing Date:</b> 03 October 2001	<b>Group:</b> 1641
	<b>Information Disclosure Statement mailed:</b> 25 April 2005	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	none					

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	none						

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Document Description
	Bhattacharya et al., "A domain-specific usherin/collagen IV interaction may be required for stable integration into the basement membrane superstruture," <i>Journal of Cell Science</i> , 117:233-242 (2004).
	Bhattacharya et al., "Localization and expression of usherin: a novel basement membrane protein defective in people with Usher's syndrome type Iia," <i>Hearing Research</i> , 163:1-11 (2002).
	Cohn et al., "Immunohistochemistry and Reverse Transcriptase-Polymerase Chain Reaction as Methods for Diagnostic Determination of Usher Syndrome Type IIa," <i>Laryngoscope</i> , 114:1310-1314 (2004).
	Pearsall et al., "Usherin expression is highly conserved in mouse and human tissues," <i>Hearing Research</i> , 174:55-63 (2002).

<b>EXAMINER</b>	<b>Date Considered</b>
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	